Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial.
Carmen Lúcia Kuniyoshi RebelattoAlexandra Cristina SenegagliaClaudio Luciano FranckDebora Regina DagaPatrícia ShigunovMarco Augusto StimamiglioDaniela Boscaro MarsaroBruna SchaidtAndressa MicoskyAna Paula de AzambujaCleverson Alex LeitãoRicardo Rasmussen PetterleValderez Ravaglio JamurIsadora May VazAntônio Paulo MallmannHipólito Carraro JuniorEduardo DitzelPaulo Roberto Slud BrofmanAlejandro CorreaPublished in: Stem cell research & therapy (2022)
UC-MSCs infusion is safe and can play an important role as an adjunctive therapy, both in the early stages, preventing severe complications and in the chronic phase with postacute sequelae reduction in critically ill COVID-19 patients. Trial registration Brazilian Registry of Clinical Trials (ReBEC), UTN code-U1111-1254-9819. Registered 31 October 2020-Retrospectively registered, https://ensaiosclinicos.gov.br/rg/RBR-3fz9yr.